Cargando…
Ileal Bile Acid Transporter Inhibition Reduces Post-Transplant Diarrhea and Growth Failure in FIC1 Disease—A Case Report
Familial intrahepatic cholestasis 1 (FIC1) disease is a genetic disorder characterized by hepatic and gastrointestinal disease due to ATP8B1 deficiency, often requiring liver transplantation (LT). Extrahepatic symptoms, such as diarrhea, malabsorption, and failure to thrive, do not improve and inste...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139332/ https://www.ncbi.nlm.nih.gov/pubmed/35626847 http://dx.doi.org/10.3390/children9050669 |
_version_ | 1784714834960449536 |
---|---|
author | Ohlendorf, Johanna Goldschmidt, Imeke Junge, Norman Laue, Tobias Nasser, Hamoud Jäckel, Elmar Mutschler, Frauke Pfister, Eva-Doreen Herebian, Diran Keitel, Verena Baumann, Ulrich |
author_facet | Ohlendorf, Johanna Goldschmidt, Imeke Junge, Norman Laue, Tobias Nasser, Hamoud Jäckel, Elmar Mutschler, Frauke Pfister, Eva-Doreen Herebian, Diran Keitel, Verena Baumann, Ulrich |
author_sort | Ohlendorf, Johanna |
collection | PubMed |
description | Familial intrahepatic cholestasis 1 (FIC1) disease is a genetic disorder characterized by hepatic and gastrointestinal disease due to ATP8B1 deficiency, often requiring liver transplantation (LT). Extrahepatic symptoms, such as diarrhea, malabsorption, and failure to thrive, do not improve and instead may be aggravated after LT. We describe a patient with FIC1 disease who underwent LT at 2 years, 8 months of age. After LT, the child developed severe refractory diarrhea and failed to thrive. The response to bile acid resins was unsatisfactory, and the parents declined our recommendation for partial external biliary diversion (PEBD). Quality of life was extremely impaired, especially due to severe diarrhea, making school attendance impossible. Attempting to reduce the total bile acids, we initiated off-label use of the ileal bile acid transporter (IBAT) inhibitor Elobixibat (Goofice(™)), later converted to Odevixibat (Bylvay(™)). After six months of treatment, the patient showed less stool output, increased weight and height, and improved physical energy levels. The child could now pursue higher undergraduate education. In our patient with FIC1 disease, the use of IBAT inhibitors was effective in treating chronic diarrhea and failure to thrive. This approach is novel; further investigations are needed to clarify the exact mode of action in this condition. |
format | Online Article Text |
id | pubmed-9139332 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91393322022-05-28 Ileal Bile Acid Transporter Inhibition Reduces Post-Transplant Diarrhea and Growth Failure in FIC1 Disease—A Case Report Ohlendorf, Johanna Goldschmidt, Imeke Junge, Norman Laue, Tobias Nasser, Hamoud Jäckel, Elmar Mutschler, Frauke Pfister, Eva-Doreen Herebian, Diran Keitel, Verena Baumann, Ulrich Children (Basel) Case Report Familial intrahepatic cholestasis 1 (FIC1) disease is a genetic disorder characterized by hepatic and gastrointestinal disease due to ATP8B1 deficiency, often requiring liver transplantation (LT). Extrahepatic symptoms, such as diarrhea, malabsorption, and failure to thrive, do not improve and instead may be aggravated after LT. We describe a patient with FIC1 disease who underwent LT at 2 years, 8 months of age. After LT, the child developed severe refractory diarrhea and failed to thrive. The response to bile acid resins was unsatisfactory, and the parents declined our recommendation for partial external biliary diversion (PEBD). Quality of life was extremely impaired, especially due to severe diarrhea, making school attendance impossible. Attempting to reduce the total bile acids, we initiated off-label use of the ileal bile acid transporter (IBAT) inhibitor Elobixibat (Goofice(™)), later converted to Odevixibat (Bylvay(™)). After six months of treatment, the patient showed less stool output, increased weight and height, and improved physical energy levels. The child could now pursue higher undergraduate education. In our patient with FIC1 disease, the use of IBAT inhibitors was effective in treating chronic diarrhea and failure to thrive. This approach is novel; further investigations are needed to clarify the exact mode of action in this condition. MDPI 2022-05-05 /pmc/articles/PMC9139332/ /pubmed/35626847 http://dx.doi.org/10.3390/children9050669 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Ohlendorf, Johanna Goldschmidt, Imeke Junge, Norman Laue, Tobias Nasser, Hamoud Jäckel, Elmar Mutschler, Frauke Pfister, Eva-Doreen Herebian, Diran Keitel, Verena Baumann, Ulrich Ileal Bile Acid Transporter Inhibition Reduces Post-Transplant Diarrhea and Growth Failure in FIC1 Disease—A Case Report |
title | Ileal Bile Acid Transporter Inhibition Reduces Post-Transplant Diarrhea and Growth Failure in FIC1 Disease—A Case Report |
title_full | Ileal Bile Acid Transporter Inhibition Reduces Post-Transplant Diarrhea and Growth Failure in FIC1 Disease—A Case Report |
title_fullStr | Ileal Bile Acid Transporter Inhibition Reduces Post-Transplant Diarrhea and Growth Failure in FIC1 Disease—A Case Report |
title_full_unstemmed | Ileal Bile Acid Transporter Inhibition Reduces Post-Transplant Diarrhea and Growth Failure in FIC1 Disease—A Case Report |
title_short | Ileal Bile Acid Transporter Inhibition Reduces Post-Transplant Diarrhea and Growth Failure in FIC1 Disease—A Case Report |
title_sort | ileal bile acid transporter inhibition reduces post-transplant diarrhea and growth failure in fic1 disease—a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139332/ https://www.ncbi.nlm.nih.gov/pubmed/35626847 http://dx.doi.org/10.3390/children9050669 |
work_keys_str_mv | AT ohlendorfjohanna ilealbileacidtransporterinhibitionreducesposttransplantdiarrheaandgrowthfailureinfic1diseaseacasereport AT goldschmidtimeke ilealbileacidtransporterinhibitionreducesposttransplantdiarrheaandgrowthfailureinfic1diseaseacasereport AT jungenorman ilealbileacidtransporterinhibitionreducesposttransplantdiarrheaandgrowthfailureinfic1diseaseacasereport AT lauetobias ilealbileacidtransporterinhibitionreducesposttransplantdiarrheaandgrowthfailureinfic1diseaseacasereport AT nasserhamoud ilealbileacidtransporterinhibitionreducesposttransplantdiarrheaandgrowthfailureinfic1diseaseacasereport AT jackelelmar ilealbileacidtransporterinhibitionreducesposttransplantdiarrheaandgrowthfailureinfic1diseaseacasereport AT mutschlerfrauke ilealbileacidtransporterinhibitionreducesposttransplantdiarrheaandgrowthfailureinfic1diseaseacasereport AT pfisterevadoreen ilealbileacidtransporterinhibitionreducesposttransplantdiarrheaandgrowthfailureinfic1diseaseacasereport AT herebiandiran ilealbileacidtransporterinhibitionreducesposttransplantdiarrheaandgrowthfailureinfic1diseaseacasereport AT keitelverena ilealbileacidtransporterinhibitionreducesposttransplantdiarrheaandgrowthfailureinfic1diseaseacasereport AT baumannulrich ilealbileacidtransporterinhibitionreducesposttransplantdiarrheaandgrowthfailureinfic1diseaseacasereport |